XCUR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exicure Inc (XCUR) is not a good buy for a beginner investor with a long-term strategy at this time. The company's financial performance is poor, with declining revenue, net income, and EPS. Insider selling has increased significantly, and technical indicators suggest a bearish trend. While the recent co-development agreement with Adbiotech is a positive catalyst, it is not sufficient to outweigh the negative financial and technical factors. Additionally, no Intellectia Proprietary Trading Signals are present for this stock today.
The stock is in a bearish trend, with the MACD histogram below 0 and negatively contracting. RSI is neutral at 27.741, and moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are Pivot: 3.794, R1: 3.985, S1: 3.603, R2: 4.103, S2: 3.485. The stock has a 60% chance to decline in the next day (-0.12%), week (-2.41%), and month (-9.89%).
The company announced a co-development agreement with Adbiotech for Burixafor, targeting hematological diseases. Burixafor has completed a Phase 2 clinical trial in multiple myeloma, which could provide a foundation for further development.
Insiders are selling heavily, with a 106.79% increase in selling activity over the last month. The company's financials show significant declines in revenue, net income, EPS, and gross margin. Technical indicators suggest a bearish trend.
In 2025/Q4, revenue was stagnant at $0 (0.00% YoY). Net income dropped to -$2,898,000 (-59.64% YoY), EPS fell to -0.45 (-83.64% YoY), and gross margin dropped to 0 (-100.00% YoY).
No recent analyst rating or price target changes are available for XCUR.
